

REFERENCES

1. Bergqvist Y. High-Performance Liquid Chromatographic assay for the simultaneous monitoring of mefloquine and its acid metabolite in biological samples using protein precipitation and ion pair extraction. *Journal of Chromatography* 1988; 432: 253-263.
2. Crevoisier C, Handschin J, Barre J, Roumenov D, Kleinbloesem C. Food increases the bioavailability of mefloquine. *European Journal of Clinical Pharmacology* 1997; 53: 135-139.
3. Edstein MD, Lika, ID, Chongsuphajaisiddhi T, Subchareon A, Webster HK. "Quantitation of Fansimef Components (Mefloquine + Sulfadoxine + Pyrimethamine) in Human plasma by Two High-Performance Liquid Chromatographic Methods. *Therapeutic Drug Monitoring* 1991; 13: 146-151.
4. Foster S. Economic prospects for a new antimalarial drug. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1994; 55 (suppl. 1): 55-56.
5. Goldsmith RS. Antiprotozoal Drugs. In: *Basic and Clinical Pharmacology*. Katzung, B.G., ed. 5th. Englewood Cliffs : Prentice-Hall International Inc., 1992; 723-747.
6. Goldsmith RS. Antiprotozoal Drugs. In: *Basic and Clinical Pharmacology*. Katzung, B.G., ed. 7th. New Jersey : Prentice-Hall International Inc., 1998; 723-747.
7. Gonzalez FJ, Idle JR. Pharmacogenetic Phenotyping and Genotyping Present Status and Future Potential. *Clinical Pharmacokinetics* 1994; 26: 59-70.

8. Harinasuta T, Bunnag D, Wernsdorfer WH. A phase 2 clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand. *Bull WHO* 1983; 61: 299-305.
9. Karbwang J, White NJ. Clinical Pharmacokinetics of mefloquine. *Clinical Pharmacokinetics* 1990; 19: 264-279.
10. Karbwang J, Back DJ, Bunnag D, Breckenridge AM. A comparison of the pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients with falciparum malaria. *European Journal of Clinical Pharmacology* 1988; 35: 677-680.
11. Karbwang J. et al. Effect of Oral Contraceptive Steroids on the Clinical course of Malaria Infection and on the Pharmacokinetics of Mefloquine in Thai women. *Bull WHO* 1988; 66: 763-767.
12. Karbwang J, Na Bangchang K, Bach D.J, Bunnag, D. Effect of ampicillin on mefloquine pharmacokinetics in Thai males. *European Journal of Clinical Pharmacology* 1991; 40: 631-633.
13. Karbwang J, Na Bangchang K, Thanavibul A, Back DJ, Bunnag, D. Pharmacokinetics of mefloquine in the presence of Primaquine. *European Journal of Clinical Pharmacology* 1992; 42: 559-560.
14. Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine : Clinical implications. *Clinical Pharmacokinetics* 1996; 30: 263-299.
15. Lobel HO, Miani M, Eng T, Bernard KW, Hightower AW, Campbell CC. Long-term malaria prophylaxis with weekly Mefloquin. *Lancet* 1993; 341: 848-851.

16. Mansor SM, Naravatnam V, Mohamad M, Hussein S, Kumar A et al. Single dose kinetic study of the triple combination mefloquine-sulfadoxine-pyrimethamine (Fansimef) in healthy male volunteers. *British Journal of clinical Pharmacology* 1989; 27: 381-386.
17. Mirghani RA, Hellgren U, Westerberg PA, Ericsson O, Bertilsson, L, Gustafsson LL. The roles of Cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. *Clinical Pharmacology and Therapeutics* 1999; 66: 454-460.
18. Nosten F, Price RN. New Antimalarials A Risk-Benefit Analysis. *Drug Safety* 1995; 12: 264-273.
19. Spinler SA, Cheng JWM, Kindwall KE. Possible inhibition of hepatic metabolism of quinidine by erythromycin. *Clinical Pharmacology and Therapeutics* 1995; 57: 89-94.
20. Strayhorn VA, Bacicwicz AM, Self TH. Update on rifampin Drug Interactions III. *Archive Internal Medicine* 1997; 157: 2453-2458.
21. Sunbhanich M, Ridditid W, Wongnawa M, Akesiripong S, Chamnongchob P. Effect of cimetidine on an oral single-dose mefloquine pharmacokinetics in humans. *Asia Pacific Journal of Pharmacology* 1997; 12: 51-55.
22. Venkatesan K. Pharmacokinetic Drug Interactions with Rifampicin. *Clinical Pharmacokinetic* 1992; 22: 47-65.

23. Villikka K, Kivisto KT, Backman JT, Olkkola KT, Neuvonen P.J.
Triazolam is ineffective in patients taking rifampin. *Clinical Pharmacology and Therapeutics* 1997; 61: 8-14.
24. Wanwimolruk S, Kang W, Coville PF, Viriyayudnakorn S, Thitiarenakul S. Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man. *Journal of Clinical Pharmacology* 1995; 40: 87-91.
25. Wanwimolruk S, Wong SM, Znang H, Coville PF, Walker RJ. Metabolism of Quinine in Man : Identification of a Major Metabolite, and Effects of Smoking and Rifampicin Pretreatment. *Journal of Pharmacy and Pharmacology* 1995; 47: 957-963.
26. Weidekamm E, Rusing G, Caplain H, Sorgel F, Crevoisier C. Lack of bioequivalence of a generic mefloquine tablet with the standard product. *European Journal of Clinical Pharmacology* 1998; 54: 615-619.
27. Wildt SN, Kearns GL, Leeder JS, Anker JN. Cytochrome P450 3A Ontogeny and Drug Disposition. *Clinical Pharmacokinetics* 1999; 37: 485-505.